BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $920,400 | +102.1% | 130,000 | +100.9% | 0.00% | +33.3% |
| Q2 2023 | $455,488 | -35.7% | 64,700 | -23.9% | 0.00% | 0.0% |
| Q1 2023 | $708,900 | +147.0% | 85,000 | +240.0% | 0.00% | 0.0% |
| Q4 2022 | $287,000 | -74.8% | 25,000 | -82.1% | 0.00% | -80.0% |
| Q1 2019 | $1,140,000 | +8.7% | 140,000 | +7.7% | 0.02% | +7.1% |
| Q4 2018 | $1,049,000 | -37.5% | 130,000 | -40.9% | 0.01% | -33.3% |
| Q3 2018 | $1,679,000 | -2.3% | 220,000 | -26.7% | 0.02% | -12.5% |
| Q2 2018 | $1,719,000 | -35.6% | 300,000 | -46.4% | 0.02% | -56.4% |
| Q1 2018 | $2,671,000 | – | 560,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |